Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 9:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Enhanced drug labeling Clear all
Completed Phase 2Phase 3 Interventional Results available

Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab Plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma

NCT04396860
View directory record Official record
Conditions
Gliosarcoma, MGMT-Unmethylated Glioblastoma
Interventions
Contrast-enhanced Magnetic Resonance Imaging, Ipilimumab, Nivolumab, NovoTTF-100A Device, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Temozolomide
Procedure · Biological · Device + 3 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
285
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Anaheim, California + 210 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 28, 2026, 9:04 PM EDT
Terminated Phase 1 Interventional

The Seven Trial: Exploiting the Unfolded Protein Response

NCT06076837
View directory record Official record
Conditions
Pancreatic Cancer Metastatic, Pancreatic Adenocarcinoma Metastatic
Interventions
Botensilimab, Balstilimab, Chloroquine Phosphate, Celecoxib, Nab paclitaxel, Gemcitabine, Cisplatin
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Sep 28, 2026, 9:04 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Contrast-Enhanced Ultrasound in Human Crohn's Disease

NCT02061163
View directory record Official record
Conditions
Crohn's Disease
Interventions
Contrast Enhanced Ultrasound, Optison
Device · Drug
Lead sponsor
University of Michigan
Other
Eligibility
10 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 14, 2015 · Synced Sep 28, 2026, 9:04 PM EDT
Not yet recruiting No phase listed Observational

Microvasculature Ultrasound Super-resolution in Transplant Delayed Graft Function

NCT07645599
View directory record Official record
Conditions
End Stage Chronic Renal Failure, Renal Transplant, Microvascular Changes, Microvascular Circulation
Interventions
Ultrasound contrast agent (Contrast-enhanced ultrasound), Optison (Perflutren Protein-Type A Microspheres Injectable Suspension), Lumason® contrast agent, DEFINITY®
Diagnostic Test · Drug
Lead sponsor
Roderick Tan
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Sep 28, 2026, 9:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Improving Prescription Drug Warning Labels

NCT00846209
View directory record Official record
Conditions
Enhanced Text, Enhanced Text + Icon
Interventions
Enhanced drug labeling
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 13, 2023 · Synced Sep 28, 2026, 9:04 PM EDT
Completed Phase 2 Interventional Results available

Study Comparing the Safety and Efficacy of Belatacept With That of Cyclosporine in Patients With a Transplanted Kidney

NCT00035555
View directory record Official record
Conditions
Graft Rejection, Kidney Transplantation, Renal Transplantation
Interventions
Belatacept, Cyclosporine, Mycophenolate mofetil (MMF), Corticosteroids
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2012
U.S. locations
12
States / cities
San Francisco, California • Atlanta, Georgia • Baltimore, Maryland + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Sep 28, 2026, 9:04 PM EDT
Completed Not applicable Interventional Results available

FMISO PET Study of Glioblastoma

NCT02076152
View directory record Official record
Conditions
Recurrent Glioblastoma
Interventions
FMISO PET, MRI, Bevacizumab, CCNU
Device · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2021 · Synced Sep 28, 2026, 9:04 PM EDT
Completed Phase 4 Interventional

Dotarem vs Gadobutrol Contrast for Breast MRI

NCT03730051
View directory record Official record
Conditions
Breast Diseases
Interventions
Gadoterate meglumine, Gadobutrol
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years and older · Female only
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 28, 2026, 9:04 PM EDT
Completed Not applicable Interventional

Enhancing Self-Management Support in Diabetes Through Patient Engagement

NCT02834923
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Enhanced Engagement Protocol for CTH (EE-CTH), Connection to Health (CTH)
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
725 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Feb 22, 2021 · Synced Sep 28, 2026, 9:04 PM EDT
Completed Phase 3 Interventional

Phase 3 Safety and Imaging Study of AI-700 in Patients With Suspected Coronary Artery Disease Undergoing Coronary Angiography

NCT00156845
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
AI-700 contrast-enhanced echocardiography
Procedure
Lead sponsor
Acusphere
Industry
Eligibility
18 Years to 80 Years
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2006 · Synced Sep 28, 2026, 9:04 PM EDT
Completed Phase 3 Interventional

Phase 3 Imaging and Safety Study of AI-700 in Patients With Suspected Coronary Artery Disease Undergoing SPECT Imaging

NCT00156793
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
AI-700 contrast-enhanced echocardiography
Procedure
Lead sponsor
Acusphere
Industry
Eligibility
18 Years to 80 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Watertown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2006 · Synced Sep 28, 2026, 9:04 PM EDT
Completed Phase 2 Interventional Results available

Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

NCT00818441
View directory record Official record
Conditions
Carcinoma, Non-small Cell
Interventions
Dacomitinib (PF-00299804)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
31
States / cities
Orange, California • Pleasant Hill, California • Salinas, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2019 · Synced Sep 28, 2026, 9:04 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC

NCT04032847
View directory record Official record
Conditions
Advanced Non Small Cell Lung Cancer
Interventions
ATL001, Pembrolizumab
Biological · Drug
Lead sponsor
Achilles Therapeutics UK Limited
Industry
Eligibility
18 Years to 75 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
3
States / cities
New Haven, Connecticut • Tampa, Florida • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 9, 2025 · Synced Sep 28, 2026, 9:04 PM EDT
Completed Not applicable Interventional

Interleukin-2 (IL-2) Treatment for HIV Infected Patients Who Have Interrupted Their Anti-HIV Drug Therapy

NCT00038259
View directory record Official record
Conditions
HIV Infections
Interventions
Aldesleukin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2006
U.S. locations
10
States / cities
Los Angeles, California • Palo Alto, California • Sacramento, California + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 28, 2026, 9:04 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of NX9 for Delineation of Bowel Anatomy

NCT04789200
View directory record Official record
Conditions
GI Carcinoma, GI Disorders
Interventions
NX9 Oral Contrast Agent
Drug
Lead sponsor
Nextrast, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Rochester, Minnesota • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 17, 2022 · Synced Sep 28, 2026, 9:04 PM EDT
Completed No phase listed Observational

Cystic Breast Masses by Contrast Enhanced Ultrasound (CEUS)

NCT02887937
View directory record Official record
Conditions
Breast Cancer
Interventions
Definity
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Sep 28, 2026, 9:04 PM EDT
Completed Phase 1 Interventional

Study of AGEN1571 in Participants With Advanced Solid Tumors

NCT05377528
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
AGEN1571, Balstilimab, Botensilimab
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Los Angeles, California • Denver, Colorado • Sarasota, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 28, 2026, 9:04 PM EDT
Terminated Phase 3 Interventional Results available

Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent

NCT02084628
View directory record Official record
Conditions
Magnetic Resonance Imaging
Interventions
Gadoxetate disodium (Eovist/Primovist, BAY86-4873)
Drug
Lead sponsor
Bayer
Industry
Eligibility
Up to 2 Months
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
9
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Sep 28, 2026, 9:04 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Investigation of Efficacy of Improved Acetaminophen Labeling

NCT01592448
View directory record Official record
Conditions
Acetaminophen Overdose, Pain
Interventions
Active Ingredient Icon
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 80 Years
Enrollment
662 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
4
States / cities
Atlanta, Georgia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 17, 2014 · Synced Sep 28, 2026, 9:04 PM EDT
Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Efficacy of SAR446523 Injected Subcutaneously in Adult Participants With Relapsed/Refractory Myeloma

NCT06630806
View directory record Official record
Conditions
Plasma Cell Myeloma Refractory
Interventions
SAR446523
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2031
U.S. locations
5
States / cities
Phoenix, Arizona • Jacksonville, Florida • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Sep 28, 2026, 9:04 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Contrast-enhanced Ultrasound of the Kidney

NCT02684435
View directory record Official record
Conditions
Chronic Kidney Disease, Cystic Kidney Disease
Interventions
Perflutren lipid microsphere
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Sep 28, 2026, 9:04 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Near-Infrared Image Guided Surgical Resection With Indocyanine Green in Treating Patients With Head and Neck Cancer

NCT03745690
View directory record Official record
Conditions
Head and Neck Carcinoma
Interventions
Image-Guided Surgery, Indocyanine Green Drug
Procedure · Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Sep 28, 2026, 9:04 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories

NCT05514509
View directory record Official record
Conditions
HIV Infections
Interventions
APRETUDE, Cabotegravir tablet
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older · Female only
Enrollment
370 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
22
States / cities
Washington D.C., District of Columbia • Miami, Florida • Orlando, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 8, 2026 · Synced Sep 28, 2026, 9:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Open-Label Pilot Study of Lisdexamfetamine for Cocaine Dependence

NCT01486810
View directory record Official record
Conditions
Cocaine Dependence
Interventions
Lisdexamfetamine, medication management
Drug · Behavioral
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Sep 28, 2026, 9:04 PM EDT